# BPC-157 Research History Croatian Lab

URL: https://moleculenotes.com/clinical-evidence-and-mechanisms/bpc-157-research-history-croatian-laboratory
Published: 2026-07-24
Updated: 2026-07-24
Author: Admin
Category: Clinical Evidence & Mechanisms
Reading time: 15 min

> Explore how Zagreb's Department of Pharmacology built a decades-long research program around a gastric peptide. Read the institutional history.

---

The University of Zagreb School of Medicine sits in a city that, in the early 1990s, was navigating the upheaval of Yugoslav dissolution while its academic institutions tried to maintain continuity in basic research. Inside the Department of Pharmacology, Professor Dijalma Sikiric's group was pursuing a question that, on the surface, sounded almost philosophical: could the stomach's own proteins encode sequences capable of protecting tissue from injury? It was a credible question. It was also one that would take three decades, roughly 150 peer-reviewed papers, and a winding path through rodent tendons, corneal tissue, and spinal cord models before anyone could say with confidence what the answer was, or whether an answer had arrived at all.

This is an institutional history, not a compound profile. The compound in question is BPC-157, a synthetic pentadecapeptide that has accumulated one of the more unusual evidence bases in contemporary peptide biology. It has never been approved as a therapeutic agent in any jurisdiction. It has never completed a Phase II or Phase III clinical trial. And yet, the BPC-157 research history Croatian laboratory produced spans tissue systems from the gastrointestinal tract to the peripheral nervous system, generating a body of preclinical literature that independent researchers have only partially examined.

The central tension is worth naming at the outset. A peptide derived from gastric juice protein, studied with apparent methodological rigor inside one pharmacology department in Zagreb, has simultaneously attracted serious mechanistic interest from a small community of biomedical researchers and become a staple of the global biohacking market. How that happened, and what it reveals about the structure of contemporary peptide research, is the story worth following.

## BPC-157 Research History: Croatian Laboratory Origins and Gastric Ulcer Work

The stomach's ability to resist its own acid had puzzled physiologists for well over a century before Sikiric's group began formal peptide work in Croatia. The gastric mucosa sits in a microenvironment of concentrated hydrochloric acid and proteolytic enzymes capable of digesting protein, yet the tissue survives intact under normal conditions. That survival depends on a coordinated cytoprotective system, and by the 1980s, researchers had begun to identify some of its molecular components.

The cytoprotection concept itself had been formalized largely through the work of Andre Robert at Upjohn in the late 1970s, who characterized [prostaglandin-mediated mucosal defense](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014680/). By the early 1990s, the field had moved toward asking whether endogenous proteins in gastric secretions might themselves encode protective signals. Sikiric's group, working at the University of Zagreb School of Medicine's Department of Pharmacology and funded in part through Croatian Ministry of Science grants, framed their early research inside that question.

The hypothesis was grounded in legitimate gastroenterology literature. If the gastric mucosa produced proteins adapted to the hostile chemistry of the stomach, then those proteins might contain peptide subsequences with intrinsic tissue-protective activity, sequences that could be isolated, characterized, and tested in injury models. The tools to do this kind of work at a regional European university had become feasible by the early 1990s: [solid-phase peptide synthesis, developed in the 1960s by Bruce Merrifield](https://www.britannica.com/technology/solid-phase-synthesis) and now widely accessible, made it possible to produce short synthetic peptides based on protein subsequences without requiring large biochemical infrastructure.

The scientific climate was permissive in a productive sense. Peptide biology had advanced enough that sequence-isolation work was tractable. And gastric ulcer disease represented a genuine clinical burden, one that the pharmacology community was actively addressing following the discovery of H2 blockers and, later, proton pump inhibitors. Sikiric's group was not working at the frontier of molecular biology; they were working at a credible intersection of gastroenterology and peptide chemistry.

## What BPC-157 Is and Where the Sequence Came From

BPC-157 is a synthetic pentadecapeptide: 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence was derived from a partial region of human gastric juice protein BPC, which gave the compound its name: Body Protection Compound, 157th candidate tested. The naming convention itself suggests the scale of screening work the Zagreb group conducted before settling on this particular sequence for sustained study.

A critical distinction applies here. BPC-157 does not occur naturally in isolation. The sequence exists within a larger parent protein, but the 15-amino-acid fragment as a free peptide is a laboratory construct, designed and stabilized by Sikiric's group for experimental purposes. This distinguishes it from peptides isolated directly from tissue, a category that includes compounds like oxytocin or substance P, which exist as discrete signaling molecules in vivo. BPC-157 is a synthetic derivative, created to test a hypothesis about what a gastric protein subsequence might do when administered independently.

What distinguished this particular candidate from others in the Zagreb screening program was a pharmacological property that researchers in the mid-1990s found genuinely interesting. BPC-157 appeared to resist enzymatic degradation and to remain stable in human gastric juice. Most therapeutic peptides face rapid breakdown in the gastrointestinal environment; the standard pharmaceutical responses are PEGylation, which attaches polyethylene glycol chains to extend half-life, or cyclization, which closes the peptide into a ring structure resistant to exopeptidase cleavage. BPC-157 required neither modification to survive conditions that would degrade most linear peptides.

The structural basis for this stability involves the peptide's proline-rich core. Proline residues create rigid, secondary-structure-disrupting configurations that resist enzymatic cleavage at those positions, and BPC-157 contains five proline residues within its 15-amino-acid sequence. That concentration of prolines is structurally significant and helps explain why the compound attracted sustained attention from gastroenterology researchers interested in orally administrable cytoprotective agents.

## The First Decade: Ulcers, Cytoprotection, and Early Animal Models

The Zagreb group's earliest published work focused on what the institutional context predicted: gastric and duodenal ulcer models in rats. The protocols were standard for the period, using chemically induced mucosal lesions and measuring outcomes including lesion area, mucosal thickness, and inflammatory markers. The rodent studies showed that BPC-157 administration was associated with reduced lesion size and accelerated mucosal integrity in treated animals compared to controls.

From gastric ulcers, the group moved to inflammatory bowel disease models, testing BPC-157 in experimental colitis preparations. This expansion was logical; if the compound modulated cytoprotective mechanisms in the stomach, the colon represented an adjacent tissue system with analogous injury dynamics. The Zagreb group's approach, however, was notable for its pace of expansion. Rather than deepening mechanistic work on the gastric model before moving to new tissue types, they moved laterally, systematically testing the peptide across injury types.

By the late 1990s, the published animal model record showed dose-dependent effects in rodents at nanogram-to-microgram per kilogram ranges. This potency profile sits substantially below the milligram-per-kilogram dosing typical of many peptide drugs, a finding the Zagreb group highlighted as evidence of unusual biological activity. The claim attracted both interest and skepticism. Low effective doses in animal models are scientifically intriguing, but they also raise questions about assay sensitivity, blinding protocols, and reproducibility that independent replication is necessary to address.

The early publication timeline showed a lab building a body of evidence across multiple gastrointestinal targets before the end of the decade. Gastric ulcers, duodenal ulcers, colitis, esophageal injury: each system received its own series of rodent experiments, and each produced publications that extended the Zagreb group's claimed range of activity. The breadth-over-depth publication strategy was becoming visible.

## Expanding the Map: Tendons, Nerves, and Corneas

The Zagreb group's expansion beyond the gastrointestinal tract, which began appearing in the literature in the early 2000s, marks the moment when BPC-157 research history Croatian laboratory observers found most scientifically unusual. Tendon-to-bone healing, ligament repair, peripheral nerve regeneration, corneal injury, and skin wound healing all entered the study portfolio within roughly a decade of the initial gastric work. The tissue systems involved share almost no anatomical proximity to the stomach.

Most research programs do not operate this way. A laboratory that identifies cytoprotective activity in gastric mucosa would typically spend years characterizing the mechanism in that tissue before attempting replication in cartilage or the optic nerve. Sikiric's group did the reverse. The strategic logic, to the extent it is visible in the publication record, appears to have been that demonstrating breadth of effect across tissue types would build the case for a general cytoprotective mechanism rather than a tissue-specific one. Whether that logic reflects scientific ambition or a different kind of strategic calculation is a question the published record leaves open.

The proposed mechanisms that emerged alongside this expansion centered on three interacting systems. The Zagreb publications described modulation of the nitric oxide system, a plausible cytoprotective pathway given NO's established roles in vascular tone and mucosal defense. They also identified upregulation of growth factor expression, particularly in the VEGF and EGF receptor pathways, which govern angiogenesis and epithelial proliferation respectively. A third proposed axis involved interaction with FAK-paxillin signaling, a pathway implicated in cell migration and tissue remodeling.

What emerged from this mechanistic picture was not a compound with a defined receptor target but something harder to characterize: a pleiotropic modulator with apparent activity across multiple signaling systems. That characterization is simultaneously the most scientifically interesting and the most contested aspect of BPC-157. Pleiotropic activity is not implausible; many endogenous peptides act across multiple pathways. But it is also the kind of profile that requires rigorous independent replication to distinguish genuine multi-pathway modulation from artifacts of study design or publication selection.

## Roughly 150 Papers From One Lab: What That Number Means

The publication count associated with BPC-157 research stands at approximately 150 peer-reviewed papers. That figure, taken at face value, appears to represent a substantial evidence base. In context, it represents something more complicated.

The citation network for these publications is unusually concentrated. Nearly all papers either originate from the Zagreb laboratory or directly cite Zagreb papers as foundational references. In a field with normal diffusion dynamics, a 30-year research program would expect to produce a distributed citation network, with independent groups contributing a substantial fraction of the total literature. The BPC-157 literature does not show that pattern.

Some outside groups have published confirmatory animal studies. Independent researchers have reported observations consistent with the Zagreb findings on tendon healing and neuroprotective effects in rodent models, which lends the overall evidence base some external validation. However, as of available records, no independent group has run a full dose-response replication study in parallel with the original Zagreb protocols. The distinction matters: confirmatory studies using different protocols in different labs provide partial validation; parallel replication of the original protocol by an independent group would provide much stronger evidence.

The distribution of the approximately 150 papers across tissue systems shows the following approximate breakdown: gastric and gastrointestinal models account for roughly 35 percent of the total; musculoskeletal models, including tendon, ligament, and bone, account for approximately 25 percent; neurological models represent around 20 percent; ophthalmological and cardiovascular models together account for the remaining 20 percent. The breakdown illustrates the breadth-first publication strategy and shows how systematically the Zagreb group moved across tissue types over three decades.

The structural reasons for single-lab concentration are not difficult to identify. The research program was funded primarily through Croatian institutional sources. It operated within a relatively insular academic environment without sustained multicenter collaboration or large international grant funding. Peer commentators examining the evidence base have noted this concentration as a recognized limitation. It does not disqualify the findings, but it means the evidence base carries a specific structural caveat that any serious evaluation must address.

## The Clinical Translation Gap

Three decades of animal model research, spanning tissue systems from the gastric mucosa to the peripheral nervous system, have not produced a single approved clinical application. BPC-157 has never completed a Phase II or Phase III clinical trial. That fact is the defining feature of the compound's current scientific status.

A Phase II trial for inflammatory bowel disease was initiated, representing the closest the Zagreb program came to human clinical evidence. As of available records, results from that trial have not been published in a peer-reviewed journal. The entire evidence base therefore remains at the preclinical animal-model level, a classification that places BPC-157 alongside thousands of compounds that showed animal model promise and never advanced further.

The structural challenges of [clinical translation for BPC-157](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/clinical-trial) are several. Human pharmacokinetics for the compound have not been established in published literature. Without understanding how the compound is absorbed, distributed, metabolized, and eliminated in humans, designing a dose-ranging clinical trial is not straightforward. The compound's pleiotropic mechanistic profile creates additional complexity: regulatory pathways for novel therapeutics require defined mechanisms and predictable target engagement, neither of which is fully characterized for BPC-157.

The absence of a commercial sponsor is equally important. Phase III clinical trials require funding on a scale that typically requires pharmaceutical industry partnership. No pharmaceutical company has, as of available records, invested in advancing BPC-157 through the clinical trial process. Without that investment, the Zagreb program's preclinical findings have no clear pathway to human evidence generation.

This is not unusual in biomedical research. The attrition rate between animal model findings and approved therapies is substantial across the field. What is distinctive about BPC-157 is the combination of duration, volume, and stasis: 30 years of systematic animal model work, approximately 150 papers, and an unresolved clinical translation trajectory. The gap between those numbers is worth noting without forcing an explanation onto it.

## From Zagreb to Biohacker Culture: A Disconnect

Somewhere in the distance between PubMed and online forums, the BPC-157 research history Croatian laboratory produced underwent a transformation of context. The Zagreb papers became footnotes in self-experimentation communities where the compound circulates as a research chemical available for self-administration. Bodybuilding and biohacking communities have discussed it for well over a decade, referencing the animal model literature as legitimizing evidence for practices that the literature does not address and was never designed to address.

The disconnect is substantial. The Zagreb program was a carefully controlled, institutionally governed animal-model research program. It operated under standard preclinical research ethics frameworks. It made no claims about human administration. The community that has grown around BPC-157's commercial availability cites the same papers while operating in a completely different register, one defined by personal experimentation, unregulated compound sourcing, and the absence of human pharmacokinetic or safety data.

No authoritative, non-commercial narrative account of the Zagreb program's institutional history existed in widely accessible media until recently. PubMed indexes the papers but provides no synthesis. The gap between the seriousness of the original research program and the culture surrounding its outputs is not incidental; it reflects a broader pattern in which preclinical animal model findings, when they achieve a certain cultural salience, become detached from their evidentiary context and repurposed for uses that the original researchers did not study and cannot validate.

What the Zagreb laboratory produced was a serious pharmacological research program. What circulates globally under its compound's name is something substantially different. That divergence is itself a phenomenon worth documenting.

## What Three Decades in One Lab Actually Produced

The arc that began in Sikiric's pharmacology department in the early 1990s is now long enough to assess in outline, if not in final judgment. A legitimate gastroenterology research program asked a credible question about stomach protein sequences, derived a stabilized pentadecapeptide from gastric juice protein, and spent three decades systematically documenting its apparent activity across rodent models of tissue injury. The resulting literature is real, peer-reviewed, and structurally unusual in its concentration within a single institutional source.

The genuine scientific interest the compound represents should be acknowledged. Its stability profile is pharmacologically significant. Its potency in animal models, if reproducible, is notable. Its apparent activity across multiple signaling systems raises legitimate mechanistic questions. These are not trivial observations.

Alongside those observations sit the structural limitations that define the evidence base: single-lab concentration over 30 years, limited independent replication of core findings, an unresolved clinical translation trajectory, and an entire absence of published human pharmacokinetic data. The Zagreb program is neither a failed effort nor a validated therapy. It is an unusually sustained institutional project whose full significance, if any, remains unresolved.

Several independent labs are now attempting to answer replication questions with better-controlled models and greater methodological transparency. Open questions remain about what multicenter human trials would find, if funding and regulatory conditions ever align to make them possible. Whether the Zagreb program's 30-year investment ultimately produces a clinical application, or remains an unusually detailed chapter in the preclinical literature, is a question the evidence cannot yet answer.

**Stay current with peptide research as it develops.** Molecule Notes publishes in-depth analysis of the science behind compounds like BPC-157, tracing the institutional histories, mechanistic debates, and clinical translation challenges that define the field. Subscribe to the Molecule Notes newsletter to receive new research summaries, lab profiles, and critical analysis directly.